Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate

The Journal of Urology
C J GirmanM M Lieber

Abstract

We describe relationships among symptoms, prostate volume and peak urinary flow rate in an age stratified, community based random sample of white men 40 to 79 years old with no prior prostate surgery, prostate cancer or other conditions known to interfere with voiding. Symptoms were assessed with an instrument comparable to the American Urological Association symptom index. Prostate volume was estimated by transrectal ultrasonography and peak urinary flow rate was measured by a portable device. Subject age was significantly associated with symptom score but accounted for only 3% of its variation, while prostate volume and peak urinary flow rate explained only an additional 10% of the symptom variability. The odds (95% confidence interval) of moderate to severe symptoms increased with age from 1.9 (1.1 to 3.1), 2.9 (1.7 to 5.0) and 3.4 (1.8 to 6.1) for men 50 to 59, 60 to 69 and 70 to 79 years old, respectively, relative to men 40 to 49 years old. Adjusting for age, the odds of moderate to severe symptoms were 3.5 times greater for men with prostatic enlargement (more than 50 ml.) than for men with smaller prostates, while the odds were similarly increased (2.4-fold) for men not achieving a peak urinary flow rate of 10 ml. per s...Continue Reading

References

Jan 1, 1979·Scandinavian Journal of Urology and Nephrology·J T AndersenS Walter
Apr 1, 1979·British Journal of Urology·P H Abrams, D J Griffiths
Oct 26, 1978·The New England Journal of Medicine·D F Ransohoff, A R Feinstein
Dec 1, 1992·Journal of Clinical Epidemiology·R S EpsteinD Patrick
Jan 1, 1992·Epidemiologic Reviews·H A Guess
Jul 1, 1992·Cancer·L DenisJ McConnell
Oct 1, 1992·Journal of Clinical Epidemiology·S J JacobsenJ J Barboriak
Mar 1, 1990·Journal of General Internal Medicine·J B Stimson, S D Fihn
Jan 1, 1986·Scandinavian Journal of Urology and Nephrology·K M JensenN E Bille-Brahe
Nov 1, 1988·British Journal of Urology·A E HerbisonJ K Walton
Mar 1, 1989·The Journal of Urology·P H GraversenR C Bruskewitz
Jan 1, 1989·The Prostate. Supplement·T Hald
Dec 1, 1988·The American Journal of Clinical Nutrition·H W GruchowJ J Barboriak
Feb 1, 1970·British Journal of Preventive & Social Medicine·E H RangE D Acheson
Apr 1, 1983·The Journal of Urology·R BruskewitzP O Madsen
Jan 1, 1983·Urologia Internationalis·K M JensenP O Madsen
Aug 1, 1984·The Journal of Urology·P C Frimodt-MøllerR C Bruskewitz
Oct 1, 1981·Scientific American·L T Kurland, C A Molgaard
Apr 4, 1980·JAMA : the Journal of the American Medical Association·J H Ellenberg, K B Nelson
Dec 1, 1994·International Journal of Epidemiology·L A PanserS J Jacobsen
Jul 1, 1993·The Journal of Urology·C G ChuteM M Lieber
Aug 18, 1993·JAMA : the Journal of the American Medical Association·J E OesterlingM M Lieber
Sep 1, 1993·The Journal of Urology·C J GirmanM M Lieber
Jan 4, 1995·JAMA : the Journal of the American Medical Association·I B Wilson, P D Cleary
Jan 1, 1995·Ultrasound in Medicine & Biology·G N CollinsW M Garraway
Nov 1, 1989·Environmental Monitoring and Assessment·H D Kahn, M B Rubin

❮ Previous
Next ❯

Citations

Jun 1, 1993·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·E Lydick, R S Epstein
Jun 27, 2002·Current Urology Reports·P K HegartyJ M Fitzpatrick
Jul 21, 2004·Current Urology Reports·Jaspreet S Sandhu, Alexis E Te
Oct 2, 2007·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Claire HopkinsPeter Brown
Mar 7, 2006·The Journal of Urology·E David CrawfordUNKNOWN MTOPS RESEARCH Group
May 30, 2001·Urology·S A KaplanUNKNOWN Proscar Long-Term Efficacy and Safety Study Group
Dec 26, 2001·Urology·S J JacobsenM M Lieber
May 20, 1998·Urology·J V Jepsen, R C Bruskewitz
Feb 23, 1999·The Urologic Clinics of North America·H L Holtgrewe
Jul 18, 2002·European Urology·Claus G RoehrbornUNKNOWN PLESS Study Group. Proscar Long-term Efficacy and Safety Study
Apr 11, 2000·BJU International·G Williams
Apr 1, 1997·British Journal of Urology·W M Garraway, F E Alexander
Feb 20, 2007·Postgraduate Medical Journal·Stephen S Connolly, John M Fitzpatrick
Aug 28, 2013·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·Minoru SakaiToshihiko Iwamoto
Jun 28, 2014·Proceedings of the National Academy of Sciences of the United States of America·Patricia J YangDavid L Hu
Feb 7, 2014·World Journal of Urology·Amar PatelMitchell R Humphreys

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.